PT Kalbe Farma Tbk. (FRA:LCLA)

Market Cap	2.60B -27.8%
Revenue (ttm)	1.76B +7.0%
Net Income	178.39M +13.4%
EPS	0.00 +14.7%
Shares Out	n/a
PE Ratio	14.58
Forward PE	13.67
Dividend	0.00 (3.73%)
Ex-Dividend Date	Jun 4, 2025

Volume	1,500
Average Volume	n/a
Open	0.0490
Previous Close	0.0500
Day's Range	0.0490 - 0.0490
52-Week Range	0.0305 - 0.0900
Beta	n/a
RSI	47.95
Earnings Date	Mar 26, 2026

About PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company pro...

• Industry: Pharmaceutical Preparations
• Founded: 1966
• Employees: 12,784
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LCLA

Financial Performance

In 2024, PT Kalbe Farma Tbk.'s revenue was 32.63 trillion, an increase of 7.16% compared to the previous year's 30.45 trillion. Earnings were 3.24 trillion, an increase of 17.13%.

Financial numbers in IDR